TW200616978A - Quinazolinone derivatives as parp inhibitors - Google Patents
Quinazolinone derivatives as parp inhibitorsInfo
- Publication number
- TW200616978A TW200616978A TW094121737A TW94121737A TW200616978A TW 200616978 A TW200616978 A TW 200616978A TW 094121737 A TW094121737 A TW 094121737A TW 94121737 A TW94121737 A TW 94121737A TW 200616978 A TW200616978 A TW 200616978A
- Authority
- TW
- Taiwan
- Prior art keywords
- parp inhibitors
- quinazolinone derivatives
- formula
- quinazolinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04076887 | 2004-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200616978A true TW200616978A (en) | 2006-06-01 |
TWI361188B TWI361188B (en) | 2012-04-01 |
Family
ID=34928320
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094121746A TWI361689B (en) | 2004-06-30 | 2005-06-29 | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
TW094121737A TWI361188B (en) | 2004-06-30 | 2005-06-29 | Quinazolinone derivatives as parp inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094121746A TWI361689B (en) | 2004-06-30 | 2005-06-29 | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
Country Status (24)
Country | Link |
---|---|
US (5) | US8623872B2 (zh) |
EP (2) | EP1763518B1 (zh) |
JP (2) | JP4969443B2 (zh) |
KR (2) | KR101286969B1 (zh) |
CN (2) | CN1980899B (zh) |
AR (2) | AR049656A1 (zh) |
AT (2) | ATE540936T1 (zh) |
AU (2) | AU2005259188B2 (zh) |
BR (2) | BRPI0512797A (zh) |
CA (2) | CA2568835C (zh) |
DE (1) | DE602005026391D1 (zh) |
EA (2) | EA012416B1 (zh) |
ES (2) | ES2380702T3 (zh) |
HK (2) | HK1105631A1 (zh) |
IL (2) | IL180382A (zh) |
MX (2) | MXPA06014543A (zh) |
MY (2) | MY140572A (zh) |
NO (2) | NO339883B1 (zh) |
NZ (2) | NZ551840A (zh) |
SG (2) | SG154434A1 (zh) |
TW (2) | TWI361689B (zh) |
UA (2) | UA86237C2 (zh) |
WO (2) | WO2006003146A1 (zh) |
ZA (2) | ZA200610775B (zh) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005054201A1 (en) | 2003-11-20 | 2005-06-16 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
CN1882549B (zh) | 2003-11-20 | 2011-02-23 | 詹森药业有限公司 | 用作聚(adp-核糖)聚合酶抑制剂的7-苯基烷基取代的2-喹啉酮和2-喹喔啉酮 |
JP5100376B2 (ja) | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parp阻害剤としてのキナゾリンジオン誘導体 |
EA012416B1 (ru) | 2004-06-30 | 2009-10-30 | Янссен Фармацевтика Н.В. | Производные замещенного 2-алкилхиназолинона как ингибиторы parp |
BRPI0512902A (pt) | 2004-06-30 | 2008-04-15 | Janssen Pharmaceutica Nv | derivados de ftalazina como inibidores de parp |
WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
RU2447889C2 (ru) | 2005-07-18 | 2012-04-20 | Бипар Сайенсиз, Инк. | Способ лечения рака (варианты) |
AU2007292306A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
SI2805945T1 (sl) * | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
ES2381446T3 (es) * | 2007-03-08 | 2012-05-28 | Janssen Pharmaceutica, N.V. | Derivado de quinolinona como inhibidores de PARP y TANK |
ES2448870T3 (es) | 2007-10-26 | 2014-03-17 | Janssen Pharmaceutica, N.V. | Derivados de quinolina como inhibidores de PARP |
EP2217227B1 (en) | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
ES2367760T3 (es) | 2008-03-27 | 2011-11-08 | Janssen Pharmaceutica, N.V. | Derivados de quinazolinona como inhibidores de la polimerización de la tubulina. |
DK2271626T3 (en) | 2008-03-27 | 2015-02-23 | Janssen Pharmaceutica Nv | TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN |
WO2010081778A1 (en) | 2009-01-17 | 2010-07-22 | Universität Zürich | Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
CN103797006B (zh) | 2011-07-13 | 2016-01-27 | 诺华股份有限公司 | 用作端锚聚合酶抑制剂的4-哌啶基化合物 |
US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
WO2013012723A1 (en) * | 2011-07-13 | 2013-01-24 | Novartis Ag | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
CN110711188A (zh) | 2012-01-20 | 2020-01-21 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
PL2812323T3 (pl) * | 2012-02-09 | 2016-09-30 | Pochodne tetrahydro-chinazolinonowe jako inhibitory tank i parp | |
US9359367B2 (en) | 2012-07-09 | 2016-06-07 | Lupin Limited | Tetrahydroquinazolinone derivatives as PARP inhibitors |
WO2014062658A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
EP2909189B8 (en) | 2012-10-16 | 2017-04-19 | Janssen Pharmaceutica NV | Heteroaryl linked quinolinyl modulators of ror-gamma-t |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
PT3027598T (pt) * | 2013-07-31 | 2017-07-17 | Merck Patent Gmbh | Derivados de oxoquinazolinil-butanamida |
WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9346782B2 (en) | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US10272097B2 (en) | 2013-12-24 | 2019-04-30 | Virginia Commonwealth University | Uses of oxygenated cholesterol sulfates (OCS) |
WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
MA41168A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
JP6871169B2 (ja) | 2015-03-02 | 2021-05-12 | シナイ ヘルス システム | 相同組換え因子 |
EP3594343B1 (en) | 2015-07-23 | 2021-04-21 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
US20190290656A1 (en) | 2015-12-30 | 2019-09-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Pt(iv) prodrugs |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
SI3494125T1 (sl) | 2016-08-02 | 2022-10-28 | Virginia Commonwealth University | Sestavki, ki vsebujejo 5-holesten-3, 25-diol, 3-sulfat(25HC3S) ali njegovo farmacevtsko sprejemljivo sol in vsaj en cikličen oligosaharid |
EP3534957A1 (en) | 2016-11-02 | 2019-09-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
PL3562822T3 (pl) | 2016-12-30 | 2021-09-13 | Mitobridge, Inc. | Inhibitory polimerazy poli(adp-rybozy) (parp) |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
CA3096127A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
JP2021515580A (ja) | 2018-03-13 | 2021-06-24 | オンクセオOnxeo | がんの治療における獲得耐性に対抗するdbait分子 |
BR112020022006A2 (pt) * | 2018-04-30 | 2021-01-26 | Ribon Therapeutics Inc. | piridazinonas como inibidores de parp7 |
CN109251198B (zh) * | 2018-09-25 | 2019-08-23 | 郝维强 | 一种用于麻醉的药物及其制备方法和用途 |
TW202039002A (zh) * | 2018-12-07 | 2020-11-01 | 斯坦福大學托管董事會 | 缺氧標靶組成物及其與一parp抑制劑之組合以及此等的使用方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN113480536B (zh) * | 2021-04-21 | 2024-02-23 | 中国人民解放军海军军医大学 | 螺环哌啶酮类衍生物 |
CN115778960A (zh) * | 2022-08-19 | 2023-03-14 | 广州六顺生物科技有限公司 | 一种杂芳环衍生物在制备治疗或预防恶病质药物中的应用 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1006423B (de) | 1952-01-18 | 1957-04-18 | Ciba Geigy | Verfahren zur Herstellung von Hydrazinophthalazinen |
GB732581A (en) | 1952-01-18 | 1955-06-29 | Ciba Ltd | Manufacture of hydrazine compounds |
US3274194A (en) | 1963-03-29 | 1966-09-20 | Miles Lab | Quinazolinedione derivatives |
GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
US3919425A (en) | 1971-04-09 | 1975-11-11 | Miles Lab | Method of producing vasodilation using certain 3-substituted-quinazoline derivatives |
BE792206A (zh) * | 1971-12-02 | 1973-06-01 | Byk Gulden Lomberg Chem Fab | |
US3879393A (en) | 1973-06-18 | 1975-04-22 | Miles Lab | Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones |
FR2436781A1 (fr) | 1978-09-19 | 1980-04-18 | Berri Balzac | Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique |
US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
JPS5976082A (ja) | 1982-10-23 | 1984-04-28 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
JPS60120872A (ja) | 1983-12-01 | 1985-06-28 | Kyowa Hakko Kogyo Co Ltd | 新規なヘテロ環状化合物及び強心剤 |
US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
MA20387A1 (fr) | 1984-03-26 | 1985-10-01 | Janssen Pharmaceutica Nv | Pyridazinamines utiles comme agents anti-viraux et procede pour leur preparation |
DK623586A (da) | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
US5231184A (en) | 1987-11-23 | 1993-07-27 | Janssen Pharmaceutica N.V. | Pridazinamine derivatives |
US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
GB8827822D0 (en) | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
EP0391462A1 (en) | 1989-04-05 | 1990-10-10 | Janssen Pharmaceutica N.V. | Synergistic compositions containing ketanserin |
US5160727A (en) | 1990-02-13 | 1992-11-03 | Warner-Lambert Company | Tumor cell sensitization method using quinazolinedione derivatives |
IE913473A1 (en) | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
KR100259107B1 (ko) | 1992-04-23 | 2000-07-01 | 슈테펜 엘. 네스비트 | 세로토닌 5ht₂길항제로서의 4-이미도메틸-1-[2'-페닐-2'-옥소에틸]피페리딘, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
TW294595B (zh) * | 1992-11-20 | 1997-01-01 | Janssen Pharmaceutica Nv | |
EP0638567A4 (en) | 1993-02-18 | 1995-05-10 | Kyowa Hakko Kogyo Kk | ADENOSINE INHIBITORS. |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
TW445263B (en) * | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
JPH107572A (ja) | 1996-06-17 | 1998-01-13 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
DE59711622D1 (de) | 1996-09-10 | 2004-06-17 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
AU7548298A (en) | 1997-05-30 | 1998-12-30 | Meiji Seika Kaisha Ltd. | Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same |
JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
EP1026160A4 (en) | 1997-09-16 | 2003-01-22 | Takeda Chemical Industries Ltd | CONNECTIONS WITH NITROGEN-CONDENSED RINGS, METHOD FOR THEIR PRODUCTION AND MEDICINES |
US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
JP2000191659A (ja) | 1999-01-04 | 2000-07-11 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
SK10692001A3 (sk) | 1999-01-29 | 2002-01-07 | Abbott Laboratories | Diazabicyklické deriváty, ich použitie a farmaceutický prípravok s ich obsahom |
US7265115B2 (en) | 1999-01-29 | 2007-09-04 | Abbott Laboratories | Diazabicyclic CNS active agents |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
MXPA03002907A (es) | 2000-10-02 | 2003-06-24 | Janssen Pharmaceutica Nv | Antagonistas receptores metabotropicos de glutamato. |
ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
NZ531245A (en) | 2001-08-15 | 2005-09-30 | Icos Corp | 2H-phthalazin-1-ones and methods for use thereof |
AU2002363429B2 (en) * | 2001-11-07 | 2008-05-08 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
PL218788B1 (pl) | 2002-03-29 | 2015-01-30 | Janssen Pharmaceutica Nv | Znakowane radioaktywnie pochodne chinoliny i jej zastosowanie |
US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
US20050075364A1 (en) | 2003-07-01 | 2005-04-07 | Kap-Sun Yeung | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives |
CN1882549B (zh) | 2003-11-20 | 2011-02-23 | 詹森药业有限公司 | 用作聚(adp-核糖)聚合酶抑制剂的7-苯基烷基取代的2-喹啉酮和2-喹喔啉酮 |
WO2005054201A1 (en) | 2003-11-20 | 2005-06-16 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
ZA200602664B (en) | 2003-12-03 | 2007-06-27 | Cytopia Res Pty Ltd | Tubulin inhibitors |
EA010488B1 (ru) | 2003-12-05 | 2008-10-30 | Янссен Фармацевтика Н.В. | 6-замещённые 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли (адф-рибоза) полимеразы |
BRPI0417571A (pt) | 2003-12-10 | 2007-03-20 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-ciclohexil-alquila substituìda como inibidores da poli(adp-ribose) polimerase |
PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
DE102004023332A1 (de) | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
EP1750706B1 (en) | 2004-06-01 | 2016-10-05 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
BRPI0512902A (pt) | 2004-06-30 | 2008-04-15 | Janssen Pharmaceutica Nv | derivados de ftalazina como inibidores de parp |
JP5100376B2 (ja) | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Parp阻害剤としてのキナゾリンジオン誘導体 |
EA012416B1 (ru) | 2004-06-30 | 2009-10-30 | Янссен Фармацевтика Н.В. | Производные замещенного 2-алкилхиназолинона как ингибиторы parp |
BRPI0607688A2 (pt) | 2005-02-17 | 2009-09-22 | Synta Pharmaceuticals Corp | método para inibir a polimerização de tubulina em uma célula; método para tratar ou prevenir um distúrbio proliferativo em um indivìduo; método para bloquear, ocluir ou de outro modo romper o fluxo sangüìneo na neovasculatura; composto; composição farmacêutica e uso do referido método e composto |
JP5075624B2 (ja) | 2005-04-28 | 2012-11-21 | 田辺三菱製薬株式会社 | シアノピリジン誘導体及びその医薬としての用途 |
RU2008110955A (ru) | 2005-08-24 | 2009-09-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Инденоизохинолиноновые аналоги и способы их применения |
PT1984333E (pt) | 2006-02-03 | 2012-07-16 | Bionomics Ltd | Benzofuranos, benzotiofenos, benzoselenofenos e indóis substituídos e sua utilização como inibidores da polimerização da tubulina |
JP5242419B2 (ja) | 2006-02-15 | 2013-07-24 | アボット・ラボラトリーズ | ピラゾロキノロン類は強力なparp阻害薬である |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
ES2381446T3 (es) | 2007-03-08 | 2012-05-28 | Janssen Pharmaceutica, N.V. | Derivado de quinolinona como inhibidores de PARP y TANK |
WO2009002469A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
-
2005
- 2005-06-28 EA EA200700188A patent/EA012416B1/ru not_active IP Right Cessation
- 2005-06-28 AU AU2005259188A patent/AU2005259188B2/en not_active Ceased
- 2005-06-28 WO PCT/EP2005/053029 patent/WO2006003146A1/en active Application Filing
- 2005-06-28 NZ NZ551840A patent/NZ551840A/en not_active IP Right Cessation
- 2005-06-28 US US11/569,892 patent/US8623872B2/en not_active Expired - Fee Related
- 2005-06-28 CN CN2005800222595A patent/CN1980899B/zh not_active Expired - Fee Related
- 2005-06-28 AT AT05756772T patent/ATE540936T1/de active
- 2005-06-28 SG SG200904451-2A patent/SG154434A1/en unknown
- 2005-06-28 EP EP05756772A patent/EP1763518B1/en active Active
- 2005-06-28 CA CA2568835A patent/CA2568835C/en not_active Expired - Fee Related
- 2005-06-28 JP JP2007518606A patent/JP4969443B2/ja not_active Expired - Fee Related
- 2005-06-28 DE DE602005026391T patent/DE602005026391D1/de active Active
- 2005-06-28 AT AT05769923T patent/ATE498613T1/de not_active IP Right Cessation
- 2005-06-28 BR BRPI0512797-1A patent/BRPI0512797A/pt not_active Application Discontinuation
- 2005-06-28 AU AU2005259192A patent/AU2005259192C1/en not_active Ceased
- 2005-06-28 US US11/570,023 patent/US7875621B2/en not_active Expired - Fee Related
- 2005-06-28 CA CA2569826A patent/CA2569826C/en not_active Expired - Fee Related
- 2005-06-28 KR KR1020067026804A patent/KR101286969B1/ko not_active IP Right Cessation
- 2005-06-28 MX MXPA06014543A patent/MXPA06014543A/es active IP Right Grant
- 2005-06-28 NZ NZ551680A patent/NZ551680A/en not_active IP Right Cessation
- 2005-06-28 KR KR1020077000916A patent/KR101184036B1/ko not_active IP Right Cessation
- 2005-06-28 CN CN200580021337XA patent/CN1976906B/zh not_active Expired - Fee Related
- 2005-06-28 ES ES05756772T patent/ES2380702T3/es active Active
- 2005-06-28 UA UAA200613304A patent/UA86237C2/uk unknown
- 2005-06-28 BR BRPI0512790-4A patent/BRPI0512790A/pt not_active Application Discontinuation
- 2005-06-28 ES ES05769923T patent/ES2361162T3/es active Active
- 2005-06-28 EA EA200700189A patent/EA012837B1/ru not_active IP Right Cessation
- 2005-06-28 EP EP05769923A patent/EP1771422B1/en active Active
- 2005-06-28 SG SG200904452-0A patent/SG154435A1/en unknown
- 2005-06-28 WO PCT/EP2005/053034 patent/WO2006003150A1/en active Application Filing
- 2005-06-28 MX MXPA06014933A patent/MXPA06014933A/es active IP Right Grant
- 2005-06-28 JP JP2007518610A patent/JP4836946B2/ja not_active Expired - Fee Related
- 2005-06-28 UA UAA200612700A patent/UA85593C2/uk unknown
- 2005-06-29 TW TW094121746A patent/TWI361689B/zh not_active IP Right Cessation
- 2005-06-29 TW TW094121737A patent/TWI361188B/zh not_active IP Right Cessation
- 2005-06-29 MY MYPI20052980A patent/MY140572A/en unknown
- 2005-06-29 MY MYPI20052986A patent/MY148322A/en unknown
- 2005-06-29 AR ARP050102688A patent/AR049656A1/es unknown
- 2005-06-29 AR ARP050102690A patent/AR051920A1/es unknown
-
2006
- 2006-12-20 ZA ZA200610775A patent/ZA200610775B/en unknown
- 2006-12-20 ZA ZA200610772A patent/ZA200610772B/xx unknown
- 2006-12-27 IL IL180382A patent/IL180382A/en not_active IP Right Cessation
- 2006-12-28 IL IL180411A patent/IL180411A/en not_active IP Right Cessation
-
2007
- 2007-01-29 NO NO20070532A patent/NO339883B1/no not_active IP Right Cessation
- 2007-01-30 NO NO20070555A patent/NO20070555L/no unknown
- 2007-10-04 HK HK07110782.4A patent/HK1105631A1/xx not_active IP Right Cessation
- 2007-10-15 HK HK07111097.2A patent/HK1105960A1/xx not_active IP Right Cessation
-
2010
- 2010-12-03 US US12/959,750 patent/US8188103B2/en active Active
-
2013
- 2013-11-12 US US14/077,881 patent/US9522905B2/en active Active
-
2016
- 2016-11-14 US US15/350,663 patent/US10150757B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG154434A1 (en) | Quinazolinone derivatives as parp inhibitors | |
SG154432A1 (en) | Quinazolinedione derivatives as parp inhibitors | |
SG154433A1 (en) | Phthalazine derivatives as parp inhibitors | |
SG151250A1 (en) | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors | |
UA91002C2 (ru) | 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы | |
WO2008107478A8 (en) | Quinolinone derivatives as parp and tank inhibitors | |
ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
UA89618C2 (ru) | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
TW200744604A (en) | P38 MAP kinase inhibitors and methods for using the same | |
IL181271A0 (en) | Triazolophthalazine derivatives and pharmaceutical compositions containing the same | |
UA91027C2 (ru) | ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53 | |
MX2008005398A (es) | Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer. | |
SI1761520T1 (sl) | Inhibitorji kinaze | |
MX2010010406A (es) | Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina. | |
TNSN08191A1 (en) | Kinase inhibitors | |
UA85505C2 (en) | Kinase inhibitors | |
WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
EA201200891A1 (ru) | Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина | |
TW200628153A (en) | Novel compounds | |
ATE513818T1 (de) | Chinazolinonderivate als tubulinpolymerisationshemmer | |
GB0308201D0 (en) | Novel compounds | |
ATE548364T1 (de) | Aminopyrazolkinasehemmer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |